Accepted at 5:10 a.m. May, 01, 2024 by musamalik
Author: cpillu01
Co-authors: herstein.jacob
Related Note: 1481330821240
Rationale for change

Misaligned with Amboss (https://next.amboss.com/us/article/kT0mI2?q=polycythemia+vera):

98% of patients with polcythemia vera have a mutation in the JAK2 gene (gain of function) → ↑ tyrosine kinase activity → ***erythropoietin-independent proliferation*** of the myeloid cell lines → ↑ blood cell mass (erythrocytosis, thrombocytosis, and granulocytosis) → hyperviscosity and slow blood flow → ↑ risk of thrombosis and poor oxygenation.

And Robbins Pathologic Basis of Disease 10e....but no textbook references

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::29_Myeloproliferative_neoplasms::01_Polycythemia_vera #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step2_v12::Original_decks::Dorian::im::ome::heme/onc::leukemia #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::03_Polycythemia #PANCE::HEME::cytoses #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::^Systems::HemeOnc::WBC #AK_Step2_v12::#Resources_by_rotation::IM::ome::heme/onc::leukemia #AK_Step1_v12::#UWorld::COMLEX::25425 #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_WBC #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::03_White_Cells::02_Myeloproliferative_Disorders #AK_Step1_v12::#OME::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #PANCE::EOR::Family_med #AK_Step1_v12::#B&B::12_Hematology::03_White_Blood_Cells::07_Myeloproliferative_Disorders #AK_Step2_v12::#AMBOSS::zt0rT3 #AK_Step2_v12::#OME::01_Medicine::05_Hematology_Oncology::05_Leukemia #AK_Step1_v12::#Pathoma::06_WBC::04_Myeloproliferative #AK_Step1_v12::#AMBOSS::4ma3fO #AK_Step1_v12::^Other::^EXPN::BGedit #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::03_Polycythemia_Vera_&_Essential_Thrombocythemia #AK_Step1_v12::#AMBOSS::CnaqvO #AK_Step2_v12::#AMBOSS::ZF0Zg3 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::31_Polycythemia::*Polycythemia_Vera #AK_Step2_v12::#AMBOSS::-t0DT3 #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::02_Polycythemia_Vera #AK_Step1_v12::#UWorld::Step::8559 #AK_Step1_v12::#USMLERx::39393.6 #AK_Step1_v12::^Other::^FA_Updates::FA2018